A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

NCT07069335 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Olaparib 150 MG

Sponsor

Boryung Pharmaceutical Co., Ltd